Faculty Bibliography

The objective of this study was to investigate the utility of using serum gonadotropin levels to predict optimal luteinizing hormone (LH) response to gonadotropin releasing hormone agonist (GnRHa) trigger. A retrospective cohort study was performed of all GnRH-antagonist controlled ovarian hyperstimulation (COH) cycles at an academic fertility center from 2017-2020. Cycles that utilized GnRHa alone or in combination with human chorionic gonadotropin (hCG) for trigger were included. Patient and cycle characteristics were collected from the electronic medical record. Optimal LH response was defined as a serum LH ≥ 40 mIU/mL on the morning after trigger. Total sample size was 3865 antagonist COH cycles, of which 91% had an optimal response to GnRHa trigger. Baseline FSH (B-FSH) and earliest in-cycle LH (EIC-LH) were significantly higher in those with optimal response. Multivariable logistic regression affirmed association of optimal response with EIC-LH, total gonadotropin dosage, age, BMI and Asian race. There was no difference in the number of oocytes retrieved (p = 0.14), maturity rate (p = 0.40) or fertilization rates (p = 0.49) based on LH response. There was no difference in LH response based on use of combination vs. GnRHa alone trigger (p = 0.21) or GnRHa trigger dose (p = 0.46). The EIC-LH was more predictive of LH trigger response than B-FSH (p < 0.005).The optimal B-FSH and EIC-LH values to yield an optimal LH response was ≥ 5.5 mIU/mL and ≥ 1.62 mIU/mL, respectively. In an era of personalized medicine, utilizing cycle and patient characteristics, such as early gonadotropin levels, may improve cycle outcomes and provide further individualized care.

PURPOSE/UNASSIGNED:Our objective was to analyse information and sentiments posted regarding the COVID-19 vaccine on fertility-related social media. MATERIALS AND METHODS/UNASSIGNED:The first fifty accounts on Instagram and Twitter were identified with the terms: fertility doctor, fertility, OBGYN, infertility, TTC, IVF. Accounts were categorised as physician (PH), individual (ID), or fertility center/organisation (FCO). The vaccine was approved on 12/11/2020 and Instagram and Twitter posts dated 12/1/2020 - 2/28/2021 were reviewed. Posts were analysed for sentiment, mention of research studies (RS), national guidelines (NG), personal experience (PE), side effects (SE), reproductive related (RR) content and activity, including likes and comments. RESULTS/UNASSIGNED:A total of 276 accounts were included. Sentiments towards the vaccine were largely positive (PH 90.3%, ID 71.4%, FCO 70%), or neutral (PH 9.7%, ID 28.6%, FCO 30%). Instagram accounts showed an increase in activity on vaccine posts compared to baseline by likes (PH 4.86% v 3.76%*, ID 7.5% v 6.37%*, FCO 2.49% v 0.52%*) and comments (PH 0.35% v 0.28%, ID 0.90% v 0.69%,* FCO 0.10% v 0.02%*). CONCLUSION/UNASSIGNED:Most posts expressed positive sentiments towards the vaccine. Evaluating the sentiment of the COVID-19 vaccine as it relates to fertility on social media represents an opportunity for understanding both the patient's and health care professional's opinion on the subject. Given the potential devastating effects of misinformation on public health parameters, like vaccination, social media offers one avenue for healthcare professionals to engage online and work to make their presences more effective and influential.SHORT CONDENSATIONThis article analyses content and sentiments posted regarding the COVID-19 vaccine on fertility-related social media in order to offer a deeper understanding of available information and beliefs.

Background: Preimplantation genetic testing for monogenic disorders (PGT-M) can be performed on embryos prior to transfer when a variant or mutation is identified in a single gene. PGT-M has historically been utilized to evaluate embryos for severe, highly penetrant and childhood-onset diseases.¹ However, the use of PGT-M has significantly increased due to increased genetic testing³ and expanded indications.^4-5 Objective: To investigate indications, trends and outcomes when PGT-M is performed for two or more monogenic disorders simultaneously.
Material(s) and Method(s): This is a case series in a single university-based fertility center. All PGT-M cases involving testing for two or more genes as well as preimplantation genetic testing for aneuploidy (PGT-A) between January 2010 and October 2021 were reviewed. Genes 1, 2 and 3 were defined as genes of interest discovered in chronological order respectively. Primary outcomes included indication for presentation to fertility center, PGT-M indication, type of condition, age of condition onset and PGT-M inheritance pattern. Secondary outcomes included genetic result of transferred embryo and ongoing pregnancy rates defined as pregnancies greater than 20 weeks gestation divided by total single thawed euploid embryo transfers (STEET).
Result(s): This study included 363 biopsied blastocysts from 49 retrievals, in 23 patients who had 24 STEET. 56%(13/23) of patients presented between 2019 and 2021,with 30%(7/23) presenting in 2021 alone.The majority initially presented for double PGT-M[44%(10/23)]. 39%(9/23) presented initially for single PGT-M,with a second gene identified later. 4%(1/23) presented for triple PGT-M. 13%(3/23) presented for infertility with no previous genetic testing.Across the 23 patients,47 genes were tested and 34 of those were unique.The most commonly tested genes were BRCA1/2[11%(5/47)],HLA[11%(5/47)], FMR1[6%(3/47)],GJB2[6%(3/47)],MSH2[4%(2/47)] and SLC26A4[4%(2/47)].The majority of genes tested cause childhood-onset diseases[68%(32/47)]. 23% were adult-onset and 8% were variable-onset.The majority were split between autosomal dominant(AD)[38%(18/47)] and autosomal recessive(AR)[(38%)18/47]. 13%(6/47) were X-linked and 10%(5/47) were for HLA matching.PGT-M indication for first gene identified included previous child affected[30%(7/23)], carrier screening[26%(6/23)], patient affected[22%(5/23)] and partner affected[22%(5/23)].PGT-M indication for second gene identified included carrier screening[43%(10/23)], previous child affected[26%(6/23)], patient affected[22%(5/23)] and partner affected[9%(2/23)].Patients underwent an average of 2.1 retrievals. 22%(11/49) of retrievals resulted in no embryos suitable for transfer requiring an average of 1.3 additional retrievals per patient. 13%(3/23) of patients had no embryos suitable for transfer.Of the 24 embryos transferred,12/24(50%) were euploid and non-carriers,11/24(46%) were euploid and autosomal recessive carriers of one gene and 1/24(4%) was euploid female and a premutation carrier of FMR1.There were no embryos transferred that were carriers of 2 mutations. 75%(18/24) of STEET resulted in ongoing pregnancies.
Conclusion(s): From the preceding decade in our clinic, PGT-M for two or more genes increased by 43% in 2021. Over this time, there has been a shift towards more testing for AD over AR disorders due to an increase in BRCA1/2 testing. The majority of patients who attempt double or more PGT-M are able to obtain unaffected or autosomal recessive carrier euploid embryos with ongoing pregnancies despite requiring an often-increased number of cycles. We expect demand for multi-gene PGT-M to rise with increased and expanded utilization of preconception comprehensive genetic screening. Financial Support: Julia Buldo-Licciardi, M.D. - None Jacquelyn Shaw, M.D. - None Andria Besser, M.S. - None Jennifer Blakemore, M.D., M.Sc. - None REFERENCES: 1. ESHRE PGD Consortium Steering Committee. ESHRE Preimplantation Genetic Diagnosis Consortium data collection III (May 2001). Hum Reprod. 2002 Jan;17 (1) 233-46. 2. Besser AG, McCulloh D, McCaffrey C, Grifo JA. Trends in Preimplantation Genetic Testing for Monogenic Disorders (PGT-M). American Society for Reproductive Medicine Meeting 2021. Baltimore, MD. 3. Besser AG, Blakemore JK, Grifo JA, Mounts EL. Transfer of embryos with positive results following preimplantation genetic testing for monogenetic disorders (PGT-M): Experience of two high-volume fertility clinics. J Assist Reprod Genet. 2019 Sep; 36 (9) 1949-1955. 4. Baruch S, Kaufman D, Hudson KL. Preimplantation genetic screening: a survey of in vitro fertilization clinics. Fertil Steril. 2008. May; 89 (5): 1053-1058. 5. Mounts EL, Besser AG. Genetic Counseling for preimplantation genetic testing (PGT): Practical and Ethical Challenges. In Sills E, Palermo G, editors. Human Embryos and preimplantation genetic technologies. Academic Press; 2019. p 43-52.
Copyright

Objective: E2P is a technique for IVF protocols in poor responders to reduce cycle cancelation due to elevated FSH as well as increase stimulation response. Yet data is inconsistent on the impact on clinical pregnancy rates.¹ We sought to evaluate if E2P increases euploidy rates in IVF with PGTA.
Material(s) and Method(s): This is a retrospective cohort study of IVF cycles with PGTA from 3/2020-12/2021 at a single academic fertility center. E2P cycles were compared to age and AMH matched controls (CON) (1:2 ratio). The primary outcome was number of euploid embryos. Secondary outcomes were cycle start follicle stimulation hormone level (FSH), total gonadotrophin (GND) dose, number oocytes, mature oocytes (MII), fertilization rate (2PN), and number of embryos biopsied (BX). Mann Whitney and Chi-square tests were performed (p<0.05 significant). Data is reported in median (range) and percentages.
Result(s): 337 E2P cycles were compared to 674 CON. There were fewer microdose lupron (MCD) cycles in E2P patients (E2P: 88% antagonist (ANT), 12% MCD vs CON: 76% ANT, 24% MCD, p<0.01). Similar cancelation rates [E2P: 14% (47/337) vs CON: 12% (82/674), p=0.42] and poor blast formation (defined as nothing for biopsy) [E2P: 18% (60/337) vs CON: 15% (103/674), p=0.24] were seen between groups. Number of euploid embryos were similar across all SART age groups except for 38-40 years (y), with fewer euploids in E2P (Table). Cycle start FSH was lower and total GND dose was higher for E2P (p<0.05). Other cycle outcomes were not different.
Conclusion(s): E2P is a viable tool for PGTA freeze all cycles, but does not improve euploidy rate; larger studies are necessary to determine if E2P produces fewer euploids in >38y. Impact Statement: E2P cycles require higher GND dose without increased yield in euploid embryos. [Formula presented] Support: None REFERENCES: 1. Orvieto R. Pretreatment: Does it improve quantity or quality? Fertil Steril. 2022 Apr;117(4):657-663. Epub 2022 Mar 5. PMID:.
Copyright

Objective: Fragile X (FgX) is a recommended part of carrier screening with pre- and full mutations associated with a spectrum of disease including intellectual disability, tremor ataxia syndrome and premature ovarian insufficiency. Risk of expansion is categorized based on number of CGG repeats.¹ Testing for AGG interruptions can offer further risk assessment in some cases.¹ As these tests become more commonplace, our objective was to determine how often screened patients select PGT-M for FgX.
Material(s) and Method(s): This is a retrospective case series at a single academic fertility center. Electronic medical records were queried to identify patients with a positive carrier screen for FgX from 2008-2022 and those undergoing PGT-M for FgX. Assisted reproductive treatments and outcomes were reviewed. Kruskal Wallis and Chi-square statistical tests were performed (p<0.05 significant).
Result(s): 393 positive FgX reports were identified including 20 prospective oocyte donors. 63% (247/393) had an intermediate (INT) number of CGG repeats (45-54), 34% (133/393) had a premutation (PRE) (55-200 repeats) and 0.8% (3/393) had a full mutation (FUL) (>200 repeats). 61% (238/393) underwent fertility treatment at our center. PRE patients were younger (INT: 36 (17-47) vs PRE: 33 (21-44) vs FUL: 37 (37-39) years (Y), p<0.01). Anti-mullerian hormone levels were similar (INT: 1.9 (0.03-14) vs PRE: 1.5 (0.01-8.7) vs FUL: 3 (0.1-5) ng/mL, p=0.08). Only 37% (49/133) of PRE carriers underwent AGG testing to further risk stratify expansion potential, as did 2% (4/247) of INT. 25% (13/53) had 0 AGGs: 4 declined fertility treatment, 4 cryopreserved oocytes, 5 underwent PGT-M. 12% (49/393) in total underwent PGT-M: 4% INT (2/49), 73% PRE (36/49), 6% FUL (3/49). 27% (13/49) of PGT-M patients underwent AGG testing: 38% (5/13) had 0 AGG, 38% (5/13) had 1 AGG, and 23% (3/13) had 2 AGGs. 8% (4/49) additional patients were offered but declined AGG testing. 18% (9/49) of PGT-M patients had terminated an affected pregnancy prior to PGT-M. 10% (5/49) had documented family members affected or PRE carriers. Patients underwent median 2 retrieval cycles (range 0-5) and 1 embryo transfer cycle (range 0-5). 31% (14/45) of patients with completed treatment did not achieved an autologous euploid unaffected embryo for transfer; two of these patients transferred non-euploid unaffected embryos and 71% (10/14) had AMH <0.8ng/mL. 1 INT and 2 PRE female embryos were also transferred. 46% (13/28) of transfers resulted in a live birth.
Conclusion(s): PGT-M is most commonly used for PRE carriers and with a history of prior affected pregnancy or family member, with varied use of AGG testing. Patients with low ovarian reserve are less likely to achieve an autologous live birth of an unaffected embryo from PGT-M. Impact Statement: FgX premutation carriers do not have uniform uptake of AGG testing or PGT-M and require individualized counseling due to differences in risk assessment and varied assisted reproductive technology outcomes. Support: None REFERENCES:: 1. Monaghan KG, Lyon E, Spector EB; American College of Medical Genetics and Genomics. ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics. Genet Med. 2013 Jul;15(7):575-86.
Copyright

Objective: Infertility affects >100 million people worldwide; improving FC access is essential, especially for low socioeconomic and minority groups. In NYC's public hospital system, patients (pts) are referred to a fellow-led reproductive endocrinology and infertility (REI) clinic that provides consults, work-ups and ultrasound-monitored controlled ovarian hyperstimulation and ovulation induction (OI). REI referrals (REF) are in high demand limiting appointment (appt) availability¹ with new pts waiting >5 months. We developed a QIP to identify pts for OI counseling and initiation in GYN clinic.
Material(s) and Method(s): REI fellows screened all REFs, and scheduled eligible pts in GYN. QIP criteria: age <38 years (y); anti-Mullerian hormone (AMH) >2ng/mL; normal prolactin, thyroid function and hemoglobin A1C; no known reproductive issues/comorbidities requiring high risk obstetrics; <3 prior OI cycles. Eligible pts received early follicular letrozole 2.5mg for 5 days (d) in GYN and were then followed in REI's OI program. Non-eligible pts were scheduled in REI. To assess effectiveness, we retrospectively compared all REF outcomes from PRE-(3/1/21-5/31/21) to POST-(9/1/21-11/30/21) QIP as of 2/14/22. A transition period (6/1/21-8/31/21) was excluded. Primary outcome was time from REF to scheduled appt. Secondary outcomes included time from REF to OI prescription/cycle start. Statistics included Mann-Whitney, Chi-square, Fischer's exact and Two-sample t tests (p<0.05 significant).
Result(s): PRE (n=121) and POST (n=102) REFs had similar median ages [36 (interquartile range (IQR): 32-39) PRE vs 35y (IQR: 31-40) POST, p=0.73], ethnic/racial identity [56.2% (68/121) PRE vs 53.9% (55/102) POST Hispanic (p=0.79); 34.7% (42/121) PRE vs 30.4% (31/102) POST Black (p=0.59)], and rates of no prior FC [88.4% (107/121) PRE vs 93.1% (95/102) POST, p=0.15]. QIP identified pts for GYN who were younger [median age 29 (IQR: 27-33) vs 38y (IQR: 33-41), p<0.01], had higher AMHs [median 3.065 (IQR: 2.315-4.883) vs 1.230 ng/mL (IQR: 0.513-3.630), p<0.01], and had fewer comorbidities [100% (19/19) vs 72.5% (50/69), p<0.01] compared to REI. After QIP implementation, median time from REF to scheduled appt decreased from PRE 151 (IQR: 125-173) to POST 98d (IQR: 73-137) (p<0.01). For pts seen in clinic thus far, median time from REF to OI prescription decreased from 150 (IQR: 122-173) to 82d (IQR: 63-119) (p<0.01) and to 1st follicle check from 202 (IQR: 159-221) to 107d (IQR: 98-115) (p<0.04). In the POST cohort, 86.3% (88/102) of REFs had visits scheduled, with 21.6% (19/88) in GYN and 78.4% (69/88) in REI. OI was started at initial visit for 61.5% (8/13) of GYN pts vs 25.8% (8/31) of REI pts (p<0.04). 38.5% (5/13) of GYN pts met criteria for QIP, but were pending >1 blood test, while 51.6% (16/31) of REI pts were pending further work-up.
Conclusion(s): Our QIP expedited FC for all pts by reducing the time from REF to scheduled fertility appt by 35% (median of 53d) and to OI prescription/cycle start by nearly 45% (medians of 68d/95d). Impact Statement: Similar OI pathways could improve access to FC for underserved populations in broader practice settings. REFERENCES: 1 Blakemore JK, Maxwell SM, Hodes-Wertz B, Goldman KN. Access to infertility care in a low-resource setting: bridging the gap through resident and fellow education in a New York City public hospital. J Assist Reprod Genet. 2020 Jul;37(7):1545-1552.
Copyright

Objective: Patients with 5 or fewer follicles during IVF face a difficult choice: should they cancel the cycle or proceed to retrieval? Limited data exist to guide this decision. This study evaluates LBRs for retrievals with <=5 follicles at trigger.
Material(s) and Method(s): This retrospective cohort study from an academic fertility center reviewed all IVF cycles yielding <=10 oocytes from 2016-2020. Cycles were included if <=5 follicles measuring >=14 mm were verified at trigger. The primary outcome was rate of ongoing pregnancy or live birth per retrieval (LBR) after fresh or frozen transfer. Secondary outcomes were number of oocytes, mature oocytes (M2s), 2 pronuclear zygotes (2PNs), blastocysts for transfer or biopsy and euploid blastocysts (if preimplantation genetic testing for aneuploidy (PGT) was used). Statistics included Chi-squared, Fisher's exact and Kruskal Wallis tests (p<0.05 significant).
Result(s): 1502 cycles (900 with PGT) from 972 patients were included. Median age was 40 years (y) (range: 26-48). See table for outcomes. Mean oocytes, M2s, 2PNs, blastocysts and euploids differed by follicle number (FN) (p<0.001). Across all ages, there were differences in LBR associated with FN (p<0.001). For patients <35y, LBR did not differ by FN. In the 35-37y group, LBR with 2, 3 or 4 follicles was lower than LBR with 5 (p<0.01). In the 38-40y group, LBR with 3 follicles was lower than LBR with 4 or 5 (p<0.02). In the 41-42y group, LBR with 2 or 3 follicles was lower than LBR with 5 (p<0.02). In the >42y group, LBR with 4 follicles was lower than LBR with 5 (p<0.03). There were no other differences in LBR by FN.
Conclusion(s): We provide clear, specific outcomes for patients with <=5 follicles at trigger. As expected, LBR is higher with more follicles. Our data can guide patients with <=5 follicles as they weigh the emotional, physical and financial costs of retrieval. Impact Statement: Our results can help patients with 5 or fewer follicles decide whether to cancel or proceed to retrieval. Patients with <=3 follicles can be counseled that LBR is likely less than 20% if 35-40 years old and likely 5% or less if 41 years or older. [Formula presented]
Copyright

Objective: To evaluate differences in oocyte cryopreservation (OC) in BRCA 1/2 patients with and without cancer diagnoses compared to controls who underwent elective cryopreservation.
Material(s) and Method(s): This was a single-center retrospective cohort study of BRCA mutation carriers who presented for fertility preservation. A data query was performed to identify all patients who were referred to our academic center from 2006-2022 to discuss fertility preservation in the setting of known BRCA 1/2-carrier status with or without cancer diagnosis. BRCA 1/2 carriers without cancer (Group A), with cancer (Group B) and controls (Group C) were included in the study. Patient demographic information, gynecologic history, antral follicle count (AFC) and cycle characteristics were reviewed. The control group consisted of 308 patients who underwent elective OC in 2021, with a 1:10 ratio of study to control group. Primary outcomes included 1) median number of oocytes retrieved, 2) oocyte maturity rate and 3) rate of M1 or GV oocytes amongst BRCA 1/2 carriers who underwent oocyte cryopreservation compared to the control group. Secondary outcomes included 1) mean anti-mullerian hormone levels (AMH), 2) median number of stimulation days and 3) cumulative dose of exogenous FSH and hMG administered during stimulation. Data was analyzed using Kruskal-Wallis analysis and Mann Whitney U-tests. A P-value of < 0.05 was considered statistically significant.
Result(s): Of 242 BRCA 1/2 carriers who were referred to our center for fertility consultation, 103 underwent ART cycles, of which 38 completed at least 1 OC cycle (21 BRCA1, 17 BRCA2), with a total of 49 OC cycles within the study group. 7 BRCA 1/2 carriers had breast cancer at time of OC (2 BRCA1, 5 BRCA2). There was no significant difference between median numbers of oocytes retrieved amongst groups (A: 18, B: 20, C: 16, p = 0.93). Oocyte maturity also did not vary significantly between groups (A: 74.4 +/- 13.5%, B: 57.3 +/- 24.8%, C: 73.4 +/- 18.1%; p=0.3). BRCA 1/2 carriers without cancer had a higher rate of M1 oocytes compared to cancer and control groups (A: 8.9 +/- 10.4%, B: 4.5 +/- 4.8%, C: 4.7 +/- 8.9%; p=0.02). Furthermore, BRCA1/2 carriers with and without cancer had a significantly higher percent of GV oocytes (A: 8.6 +/- 11.6%, B: 10.8 +/- 11.4%, C: 0.02 +/- 0.48%; p=0.001) compared to controls. Mean AMH was significantly lower in BRCA 1/2 patients with cancer compared to those without and controls (A: 3.8 +/- 2.4, B: 1.5 +/- 1.9, C: 3.2 +/- 2.6 ng/mL; p=0.04). There was no significant difference in median number of stimulation days and cumulative dose of exogenous FSH or hMG between groups.
Conclusion(s): BRCA1/2 carrier status does not compromise stimulation cycle characteristics or oocyte maturity rates. Although BRCA1/2 carriers with and without cancer at time of cycle had higher rates of M1 and GV oocytes per OC cycle, they had similar maturity rates overall compared to controls. Impact Statement: BRCA1/2 carriers should be encouraged to pursue fertility preservation if they are interested. BRCA status and/or active breast cancer diagnosis do not negatively impact cycle characteristics or oocyte maturity potential.
Copyright

Objective: When counseling patients regarding the use of PGT-A, it is unclear whether ploidy rates among INF pts who undergo PGT-A are comparable to FT pts¹. Our objective was to evaluate PGT-A outcomes in FT compared to INF pts.
Material(s) and Method(s): This is a retrospective cohort study of the first IVF cycle of all FT pts (pts without a diagnosis of infertility) who underwent PGT-A at one academic center from 2016-2021. Pts were 3-to-1 matched by age and # of oocytes retrieved to the first cycle of INF controls. Primary outcome was euploidy rate, defined as #euploids per #biopsied blastocysts. Secondary outcomes were % mature oocytes (M2), 2PN fertilization rate, blastocyst formation rate (BFR), and # of euploid, aneuploid, and mosaic embryos. BMI, AMH, day 2 FSH and E2, total gonadotropin (GND) dose, and stimulation days were compared. Subgroup analyses compared % mosaic, aneuploid, and no diagnosis embryos. Statistical analysis included Mann-Whitney U, Fisher's exact, Chi squared tests, and multiple linear regression (p<0.05 significant).
Result(s): 283 FT pts (reason for PGT-A: 64% embryo banking, 36% single gene disorders) were matched to 849 INF pts. Median age, AMH, and day 2 E2 were equivalent among groups (p>0.1). In FT pts, median day 2 FSH was higher (6.9 vs. 6.5, p<0.01) and median BMI was lower (22.1 vs. 22.5, p<0.05). FT pts received higher median doses of GNDs (3450 vs. 3150 IUs, p<0.01), but had similar median stimulation days (p=0.19). Median number of oocytes retrieved, M2s retrieved, and biopsied blastocysts did not differ among groups (p>0.29); nor did %M2s or BFR (p>0.06). 2PN fertilization was higher in FT pts (77.7 vs. 76.2%, p<0.05). See Table for PGT-A outcomes. Euploidy rate was higher in FT pts; among non-euploid embryos, INF pts had lower aneuploidy and higher mosaicism rates. The % of pts with >1 euploid embryo was similar in both groups. A multiple linear regression model continued to show the relationship between % euploid in FT vs. INF groups, while controlling for other significant covariates (BMI, total GNDs used, day 2 FSH, and 2PN fertilization rate).
Conclusion(s): FT pts had higher euploidy rates than INF pts, suggesting that infertility is associated with a lower euploidy rate. However, among non-euploid embryos, FT pts had higher aneuploidy and lower mosaicism rates compared to INF pts. An equivalent % of FT and INF pts yielded >1 euploid embryo. Impact Statement: FT pts undergoing PGT-A can be counseled that they may have a higher euploidy rate, but INF pts are just as likely to yield >1 euploid embryo. [Formula presented] Support: No financial support to disclose. REFERENCES: Kort JD, McCoy RC, Demko Z, Lathi RB. Are blastocyst aneuploidy rates different between fertile and infertile populations?. J Assist Reprod Genet. 2018;35(3):403-408.
Copyright